Genetic Signatures (ASX:GSS) — Material Events
ASX:GSS · 12 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Genetic Signatures Accelerates US Expansion with 20% Sales SurgeMedium
Genetic Signatures posts 20% quarterly sales growth, expands US contracts, and appoints new CTO
21 Oct 2025
·Quarterly Activities Report and Appendix 4C
·85
Genetic Signatures Accelerates Growth Amid Strategic Overhaul and $20M LossMedium
Genetic Signatures reports strong revenue growth, strategic pivot to partnerships, and $20.1M net loss in FY25
25 Aug 2025
·Annual Report
·85
Genetic Signatures Unveils Automated Infectious Disease Testing AllianceMedium
Genetic Signatures partners with Tecan and Repado to launch automated infectious disease testing platform
22 July 2025
·Strategic Partnership Announcement
·85
Genetic Signatures Accelerates Growth with 63% Revenue Surge and Strategic PivotMedium
Genetic Signatures posts 63% revenue growth, cuts losses, secures first US contract, pivots automated platform strategy
25 Aug 2025
·Full Year Financial Results
·85
Genetic Signatures Charts Bold Transformation with 66% Revenue Surge in FY25Medium
Genetic Signatures reports strong FY25 growth, leadership changes, and strategic refocus at 2025 AGM
17 Nov 2025
·Annual General Meeting Presentation
·80
Genetic Signatures Secures Decade-Long Danish Contract for Gastrointestinal DiagnosticsMedium
Genetic Signatures Secures 10-Year Danish Supply Agreement for Pan-Enteric Diagnostic Assay
15 Apr 2026
·Major Contract Announcement
·80
Genetic Signatures Taps Maria Halasz to Drive Next Growth PhaseMedium
Genetic Signatures names Maria Halasz as CEO starting March 2026
2 Feb 2026
·Executive Appointment
·70
Genetic Signatures Navigates US Market Challenges Amid $4.4M Quarterly SalesMedium
Genetic Signatures reports steady quarterly sales, US leadership changes, new US contract, and $30.9M cash balance
22 July 2025
·Quarterly Activities Report and Appendix 4C
·70
Genetic Signatures Reshapes Operations to Slash Costs and Boost SalesMedium
Genetic Signatures announces restructure to cut costs by $5M and boost commercial focus
30 Mar 2026
·Organisational Restructure Announcement
·70
Genetic Signatures Advances Global Reach Amid CEO TransitionMedium
Genetic Signatures reports $3.3M Q2 sales, strong cash position, CEO departure announced
20 Jan 2026
·Quarterly Activities Report and Appendix 4C
·70
Genetic Signatures Strengthens Leadership with Anne Lockwood as Interim MDMedium
Genetic Signatures appoints Anne Lockwood as interim Managing Director to strengthen leadership
6 Feb 2026
·Executive Appointment
·70
Genetic Signatures Navigates CEO Departure Amid US Market PushMedium
Genetic Signatures CEO Allison Rossiter to depart; leadership transition underway
15 Dec 2025
·Leadership Change Announcement
·60
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Genetic Signatures (ASX:GSS) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 6 (2 Feb -> 6 Feb) 2026
7 Feb 2026
Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026
25 Jan 2026